Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report

• Ngā kaituhi matua: Boney Joseph (Author), Nicolas A. Nunez (Author), Simon Kung (Author), Jennifer L. Vande Voort (Author), Vanessa K. Pazdernik (Author), Kathryn M. Schak (Author), Stacey M. Boehm (Author), Brooke Carpenter (Author), Emily K. Johnson (Author), Grigoriy Malyshev (Author), Nathan Smits (Author), Daniel O. Adewunmi (Author), Sarah K. Brown (Author), Balwinder Singh (Author)
• Hōputu: Pukapuka
• I whakaputaina: MDPI AG, 2023-08-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Intravenous (IV) ketamine and FDA-approved intranasal (IN) esketamine are increasingly used for treatment-resistant depression (TRD). Preliminary studies have suggested a synergistic effect of ketamine and lamotrigine, although the data are inconclusive. Herein, we report the response to serial keta...